A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1441-1457

  Nguyen, Nhan T ^a,b   Vendrell, Julie A ^a,b   Poulard, Coralie ^a,b   Gyorffy, Balázs ^c,d,e   Goddard Léon, Sophie ^f   Bièche, Ivan ^g   Corbo, Laura ^a,b   Le Romancer, Muriel ^a,b   Bachelot, Thomas ^f   Treilleux, Isabelle ^b,f   Cohen, Pascale A ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e INSTITUTE OF MATERIALS AND ENVIRONMENTAL CHEMISTRY   (Hungary)

^f CENTRE LÉON BÉRARD   (France)

^g INSTITUT CURIE   (France)

Author keywords

Biomarker; Breast cancer; Endocrine therapy resistance; Estrogen Receptor ; Estrogen signalling; ZNF217

Indexed keywords

ESTROGEN RECEPTOR ALPHA; GREB1 PROTEIN; KRUPPEL LIKE FACTOR; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; ZNF217 PROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVOR; CARBOXY TERMINAL SEQUENCE; CELL FRACTIONATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TREATMENT FAILURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN RESPONSIVE ELEMENT; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HINGE REGION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL BREAST CANCER; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; OVERALL SURVIVAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

EID: 84911966248     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.05.013     Document Type: Article

References (66)

1. Akaogi K., Nakajima Y., Ito I., Kawasaki S., Oie S.H., Murayama A., Kimura K., Yanagisawa J. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha. Oncogene 2009, 28:2894-2902.
2. Badia E., Duchesne M.J., Semlali A., Fuentes M., Giamarchi C., Richard-Foy H., Nicolas J.C., Pons M. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res. 2000, 60:4130-4138.
3. Banck M.S., Li S., Nishio H., Wang C., Beutler A.S., Walsh M.J. The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics 2009, 4:100-106.
4. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J.Clin. Oncol. 2005, 23:7350-7360.
5. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Malin J., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J.Clin. Oncol. 2010, 28:3784-3796.
6. Chanrion M., Negre V., Fontaine H., Salvetat N., Bibeau F., Mac Grogan G., Mauriac L., Katsaros D., Molina F., Theillet C., et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin. Cancer Res. 2008, 14:1744-1752.
7. Collins C., Rommens J.M., Kowbel D., Godfrey T., Tanner M., Hwang S.I., Polikoff D., Nonet G., Cochran J., Myambo K., et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:8703-8708.
8. Collins C., Volik S., Kowbel D., Ginzinger D., Ylstra B., Cloutier T., Hawkins T., Predki P., Martin C., Wernick M., et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res. 2001, 11:1034-1042.
9. Cowger J.J., Zhao Q., Isovic M., Torchia J. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 2007, 26:3378-3386.
10. Cuzick J., Dowsett M., Pineda S., Wale C., Salter J., Quinn E., Zabaglo L., Mallon E., Green A.R., Ellis I.O., et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J.Clin. Oncol. 2011, 29:4273-4278.
11. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. Invitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
12. Dunkler D., Michiels S., Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur. J. Cancer 2007, 43:745-751.
13. Erdemir H.H., Li Z., Sacks D.B. IQGAP1 binds to estrogen receptor-alpha and modulates its function. J.Biol. Chem. 2014, 289:9100-9112.
14. Garcia Pedrero J.M., Del Rio B., Martinez-Campa C., Muramatsu M., Lazo P.S., Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol. Endocrinol. 2002, 16:947-960.
15. Ghayad S.E., Vendrell J.A., Ben Larbi S., Dumontet C., Bieche I., Cohen P.A. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int. J. Cancer 2010, 126:545-562.
16. Gilani R.A., Kazi A.A., Shah P., Schech A.J., Chumsri S., Sabnis G., Jaiswal A.K., Brodie A.H. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res. Treat 2012, 135:681-692.
17. Gnant M., Harbeck N., Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel) 2011, 6:136-141.
18. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., Senn H.J. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013, 24:2206-2223.
19. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011, 22:1736-1747.
20. Guiu S., Michiels S., Andre F., Cortes J., Denkert C., Di Leo A., Hennessy B.T., Sorlie T., Sotiriou C., Turner N., et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann. Oncol. 2012, 23:2997-3006.
21. Guo P., Dong X.Y., Zhao K.W., Sun X., Li Q., Dong J.T. Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells. Int. J. Cancer 2010, 126:81-89.
22. Gyorffy B., Benke Z., Lanczky A., Balazs B., Szallasi Z., Timar J., Schafer R. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res. Treat 2012, 132:1025-1034.
23. Gyorffy B., Schafer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res. Treat 2009, 118:433-441.
24. Herynk M.H., Hopp T., Cui Y., Niu A., Corona-Rodriguez A., Fuqua S.A. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions. Breast Cancer Res. Treat 2010, 122:381-393.
25. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
26. Huang G., Krig S., Kowbel D., Xu H., Hyun B., Volik S., Feuerstein B., Mills G.B., Stokoe D., Yaswen P., et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum. Mol. Genet. 2005, 14:3219-3225.
27. Krig S.R., Jin V.X., Bieda M.C., O'Geen H., Yaswen P., Green R., Farnham P.J. Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J.Biol. Chem. 2007, 282:9703-9712.
28. Krig S.R., Miller J.K., Frietze S., Beckett L.A., Neve R.M., Farnham P.J., Yaswen P.I., Sweeney C.A. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 2010, 29:5500-5510.
29. Laviolette L.A., Hodgkinson K.M., Minhas N., Perez-Iratxeta C., Vanderhyden B.C. 17beta-estradiol upregulates GREB1 and accelerates ovarian tumour progression invivo. Int. J. Cancer 2014, (in press).
30. Le Romancer M., Treilleux I., Bouchekioua-Bouzaghou K., Sentis S., Corbo L. Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids 2010, 75:560-564.
31. Letessier A., Sircoulomb F., Ginestier C., Cervera N., Monville F., Gelsi-Boyer V., Esterni B., Geneix J., Finetti P., Zemmour C., et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006, 6:245.
32. Li P., Maines-Bandiera S., Kuo W.L., Guan Y., Sun Y., Hills M., Huang G., Collins C.C., Leung P.C., Gray J.W., et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int. J. Cancer 2007, 120:1863-1873.
33. Littlepage L.E., Adler A.S., Kouros-Mehr H., Huang G., Chou J., Krig S.R., Griffith O.L., Korkola J.E., Qu K., Lawson D.A., et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012, 2:638-651.
34. Liu M., Wang G., Gomez-Fernandez C.R., Guo S. GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. PLoS One 2012, 7:e46410.
35. Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., Reid J.F., et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
36. Nait Achour T., Sentis S., Teyssier C., Philippat A., Lucas A., Corbo L., Cavailles V., Jalaguier S. Transcriptional repression of estrogen receptor alpha signaling by SENP2 in breast cancer cells. Mol. Endocrinol. 2014, 28:183-196.
37. Nielsen T.O., Parker J.S., Leung S., Voduc D., Ebbert M., Vickery T., Davies S.R., Snider J., Stijleman I.J., Reed J., et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16:5222-5232.
38. Nonet G.H., Stampfer M.R., Chin K., Gray J.W., Collins C.C., Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res. 2001, 61:1250-1254.
39. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J.Clin. Oncol. 2009, 27:1160-1167.
40. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
41. Perreard L., Fan C., Quackenbush J.F., Mullins M., Gauthier N.P., Nelson E., Mone M., Hansen H., Buys S.S., Rasmussen K., et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006, 8:R23.
42. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 1993, 15:17-35.
43. Plevova P., Cerna D., Balcar A., Foretova L., Zapletalova J., Silhanova E., Curik R., Dvorackova J. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Neoplasma 2010, 57:325-332.
44. Poulard C., Treilleux I., Lavergne E., Bouchekioua-Bouzaghou K., Goddard-Leon S., Chabaud S., Tredan O., Corbo L., Le Romancer M. Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol. Med. 2012, 4:1200-1213.
45. Quinlan K.G., Nardini M., Verger A., Francescato P., Yaswen P., Corda D., Bolognesi M., Crossley M. Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins. Mol. Cell Biol. 2006, 26:8159-8172.
46. Quinlan K.G., Verger A., Yaswen P., Crossley M. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim. Biophys. Acta 2007, 1775:333-340.
47. Rahman M.T., Nakayama K., Rahman M., Nakayama N., Ishikawa M., Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih Ie M., et al. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 2011, 118:2846-2857.
48. Saceda M., Lippman M.E., Chambon P., Lindsey R.L., Ponglikitmongkol M., Puente M., Martin M.B. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol. 1988, 2:1157-1162.
49. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 2005, 19:2671-2684.
50. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
51. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100:8418-8423.
52. Stephenson J.R., Axelrad A.A., McLeod D.L., Shreeve M.M. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin invitro. Proc. Natl. Acad. Sci. USA 1971, 68:1542-1546.
53. Subramanian K., Jia D., Kapoor-Vazirani P., Powell D.R., Collins R.E., Sharma D., Peng J., Cheng X., Vertino P.M. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol. Cell. 2008, 30:336-347.
54. Sun J., Nawaz Z., Slingerland J.M. Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Mol. Endocrinol. 2007, 21:2651-2662.
55. Tharakan R., Lepont P., Singleton D., Kumar R., Khan S. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol. Cell Endocrinol. 2008, 295:70-78.
56. Thillainadesan G., Isovic M., Loney E., Andrews J., Tini M., Torchia J. Genome analysis identifies the p15ink4b tumor suppressor as a direct target of the ZNF217/CoREST complex. Mol. Cell Biol. 2008, 28:6066-6077.
57. Thollet A., Vendrell J.A., Payen L., Ghayad S.E., Ben Larbi S., Grisard E., Collins C., Villedieu M., Cohen P.A. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol. Cancer 2010, 9:291.
58. Velarde M.C., Zeng Z., McQuown J.R., Simmen F.A., Simmen R.C. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells. Mol. Endocrinol. 2007, 21:2988-3001.
59. Vendrell J.A., Bieche I., Desmetz C., Badia E., Tozlu S., Nguyen C., Nicolas J.C., Lidereau R., Cohen P.A. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr. Relat. Cancer 2005, 12:75-92.
60. Vendrell J.A., Ghayad S., Ben-Larbi S., Dumontet C., Mechti N., Cohen P.A. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007, 26:4656-4667.
61. Vendrell J.A., Magnino F., Danis E., Duchesne M.J., Pinloche S., Pons M., Birnbaum D., Nguyen C., Theillet C., Cohen P.A. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J.Mol. Endocrinol. 2004, 32:397-414.
62. Vendrell J.A., Robertson K.E., Ravel P., Bray S.E., Bajard A., Purdie C.A., Nguyen C., Hadad S.M., Bieche I., Chabaud S., et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res. 2008, 10:R88.
63. Vendrell J.A., Thollet A., Nguyen N.T., Ghayad S.E., Vinot S., Bieche I., Grisard E., Josserand V., Coll J.L., Roux P., et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res. 2012, 72:3593-3606.
64. Vilquin P., Villedieu M., Grisard E., Larbi S.B., Ghayad S.E., Heudel P.E., Bachelot T., Corbo L., Treilleux I., Vendrell J.A., et al. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int. J. Cancer 2013, 133(7):1589-1602.
65. Wang C., Fan S., Li Z., Fu M., Rao M., Ma Y., Lisanti M.P., Albanese C., Katzenellenbogen B.S., Kushner P.J., et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res. 2005, 65:6557-6567.
66. Zhou D., Ye J.J., Li Y., Lui K., Chen S. The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha. Nucleic Acids Res. 2006, 34:5974-5986.